Nanoparticle Contract Manufacturing Market By Nanoparticle Type (Metallic Nanoparticles, Polymeric Nanoparticles, Lipid-Based Nanoparticles, Ceramic Nanoparticles, Carbon-Based Nanoparticles, Quantum Dots, Others), By Service Type (Process Development, Formulation Development, Analytical & Characterization Services, Manufacturing Services, Packaging & Labeling Services, Regulatory Consulting and Documentation), By Contract Type (Custom Manufacturing, Full-Service Manufacturing, API & Intermediate Manufacturing), By End User (Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Academic & Research Institutions, Cosmetic Companies, Food & Beverage Companies, Agrochemical Companies, Environmental Agencies), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape this market in the coming years?

The Nanoparticle Contract Manufacturing market accounted for USD 2.69 Billion in 2024 and USD 2.90 Billion in 2025 is expected to reach USD 6.15 Billion by 2035, growing at a CAGR of around 7.81% between 2025 and 2035. The Nanoparticle Contract Manufacturing market constitutes the access of an outsourced producer that focuses on the manufacturing of nanoparticles. Such firms offer services like nanoparticle formulations, scale-up, and mass production of nanoparticles employed in pharmaceuticals, cosmetics, electronics, and other sectors. The market has been motivated by the demand that is growing in nanotechnology in drug delivery, diagnostics, and material science. Contract manufacturers provide modern facilities and experience where clients would save on capital expenditure and speed up the products (time-to-market). This market is still expanding since more firms are applying nanotechnology, yet they do not have the in-house competencies to produce nanoparticles on a large scale.

What do industry experts say about the market trends?

"Safe and effective delivery of therapeutic cargo to its target tissue at a clinically relevant dose is crucial… Nanoparticle engineering must be purpose‑driven and designed around the physical and biochemical properties of the therapeutic cargo and the disease it is designed to treat."

• Dr. John Lewis, CEO of Entos Pharmaceuticals

"As we continue to see the industry evolve post‑COVID, CDMOs are increasingly viewed as strategic partners. The scientific acumen of the outsourcing provider and quality of scientific output can be the deciding factor in a program’s success or failure."

• Dr. Andrew Lewis, Chief Scientific Officer at Quotient Sciences

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the market?

Growing pharmaceutical demand for targeted drug delivery using nanoparticles.

The nanoparticle contract manufacturing market is driven by the increasing demand of the drug companies to deliver the drugs to specific targeted locations. Nanoparticles allow the delivery of drugs to particular cells or tissues, thereby increasing the efficacy of the treatment and minimising side effects. This accuracy is particularly important in cancer treatment, where being specific can prevent damage to less healthy cells. Nanoparticle-based drug delivery strategies have also been promising in improving the therapeutic index of anticancer drugs, and research and development interest is beginning to be focused on this field, as indicated by the National Cancer Institute.

The U.S. Food and Drug Administration (FDA) reports on the fact that a number of nanoparticle-based formulations have reached commercial viability and are approved. Moreover, the growing incidence of chronic diseases worldwide, as registered by the World Health Organisation (WHO), contributes to the increase in demand for high-value drug delivery products, thereby further increasing the requirements of specialised nanoparticle production. A combination of these has forced pharmaceutical companies to outsource the production of nanoparticles to contract manufacturers who specialise in producing nanoparticles that are able to conform to the regulatory standards.

Increasing R&D investments in nanotechnology by biotech and pharma companies.

Enhanced investment in research and development (R&D) in nanotechnology by the biotech and pharmaceutical firms is one of the major expansion stimulants of the nanoparticle contract manufacturing market. Apart from increasing their attention to nanoparticle-based drug delivery systems, these companies are looking towards maximising the efficiency of drugs and minimising the number of side effects and their effectiveness concerning diseases. The U.S. National Institutes of Health (NIH) point out that it has continued to increase nanotechnology research funding over the last decade, demonstrating its role in medical science.

The National Science Foundation (NSF) states that governmental spending on projects related to nanotechnology amounted to over $1.8 billion during recent years, which is a clear testimony of the governmental support of these initiatives. This funding can speed up innovation and the launch of innovations through nanoparticle formulations, increasing the demand for specialised contract manufacturing organisations (CMOs), which can produce such complex materials in quantities of high quality and regulatory compliance. Consequently, the contract manufacturing of the nanoparticle industry is growing at a fast rate, along with an increase in R&D activities on nanomedicine by the biotech and pharma industry across the globe.

Limited technical expertise in nanoparticle formulation and manufacturing processes.

One of the factors that is limiting the growth of the nanoparticle contract manufacturing market is the scarcity of technical expertise on nanoparticle formulation and manufacturing procedures. The demand for nanoparticles requires their exact regulation in terms of size and shape, and their surface properties that guarantee their effectiveness and safety, and it requires extensive expertise in the fields of nanotechnology, material science, and pharmaceutical engineering.

The U.S. National Institutes of Health (NIH) argues that the synthesis of nanoparticles requires complex processes and that a common, standardised manufacturing process has yet to emerge, placing industry-wide adoption behind schedule. The U.S. Food and Drug Administration (FDA) further adds that the bottleneck is scaling up nanoparticle production to be of the same quality and reproduce, which results in increasing costs and prolonging development processes. Constrained availability of trained personnel and high regulatory demands constrain the expansion remit of nanoparticle-producing contract manufacturing organisations (CMOs).

The learning schools, such as the Massachusetts Institute of Technology (MIT), mention the continuous work in training specialists; however, they mention that at the moment, there is a lack of connections between research and development and real production. In this way, the lack of skilled staff in nanoparticle technologies is still one of the key obstacles to the growth of the markets.

Emerging applications in gene therapy and personalized nanomedicine platforms.

An increase in the speed to develop genetic therapy and personalised nanomedicine is resulting in substantive growth of the nanoparticle contract manufacturing market. The use of nanoparticles as a delivery mode has been crucial in delivering the gene-editing tools and targeted delivery of drugs so that the current level of precision can be achieved as per the individual patient profile.

As the U.S. National Institutes of Health (NIH) reported, the NIH-sponsored clinical trials in gene therapy have grown by more than 60 percent since 2002, and this shows a growing need for high-quality and scalable production of nanoparticles. Moreover, multiple nanoparticle-based treatment applications have passed through regulatory approval of the Food and Drug Administration (FDA), testifying to the certainty of regulators towards the technology.

With the transition of personalised medicine out of the lab and into clinical practice, it is important that biotech companies without the in-house capability to create these individually tailored nanoparticles find contract manufacturers who can formulate and manufacture them on their behalf. This market has the potential to grow because governments across the globe are advancing research on advanced therapies, and the European Commission has invested close to 1 billion euros in the funding of research in personalised medicine. Therefore, nanoparticle contract manufacturing is one such industry that will help to facilitate the success of the emerging gene therapy and nanomedicine industry.

Collaborations with academic institutions for advanced nanoparticle innovations.

The nanoparticle manufacturer-academic institution partnerships are an important avenue that can be utilised to improve nanoparticle innovation, particularly in the field of contracting with manufacturers. In nanotechnology, academic institutions may be on the vanguard of developing research and development in new techniques of synthesis, functionalisation, and uses in medicine, electronics, and environmental science. Collaboration with such institutions would enable contract manufacturers to have access to novel technologies and scale them up to cut down on the cost of commercialising them.

The U.S. National Nanotechnology Initiative (NNI) has reported that over 1.8 billion per year has been spent on federal expenditures on nanotechnology research aimed at continuously supporting nanotechnology research nationwide. Moreover, renowned universities like MIT, Stanford, and UC Berkeley have their nanotechnology centres, at which thousands of research articles are published every year, leading to innovation pipelines.

Such partnerships speed the process of taking laboratory findings into the marketplace in the form of commercial products and address a growing need for scalable, high-quality production of nanoparticles in the pharmaceutical, cosmetic, and energy industries. Consequently, the nanoparticle contract manufacturing market has a promising future with a high level of funding or investment in public research and the experience gained in academic laboratories.

What are the key market segments in the industry?

Based on the Nanoparticle Type, the Nanoparticle Contract Manufacturing market has been classified into Metallic Nanoparticles, Polymeric Nanoparticles, Lipid-Based Nanoparticles, Ceramic Nanoparticles, Carbon-Based Nanoparticles, Quantum Dots, and Others. Metallic nanoparticles have taken the largest and seemingly most important share in the nanoparticle contract manufacturing market. Their wide uses in various industries (healthcare, electronics, catalysis, etc.) are the main factors of such dominance. Metallic nanoparticles, metal nanoparticles (e.g., gold nanoparticles, silver nanoparticles, and platinum nanoparticles) are desired because they provide distinct properties such as conductivity, catalytic properties, and antibacterial objectives. Their sizes and the fact that they are very versatile and well-established in sectors of diagnostics, drug delivery, and industrial catalysts show significant growth in the environment of contract manufacturing over other types of nanoparticles.

Based on the Service Type, the Nanoparticle Contract Manufacturing market has been classified into Process Development, Formulation Development, Analytical & Characterization Services, Manufacturing Services, Packaging & Labeling Services, Regulatory Consulting, and Documentation. The largest and most prominent segment that would be seen in the Nanoparticle Contract Manufacturing Market is that of the Manufacturing Services. The reason is that the main applications revolve around nanoparticle synthesis on a large scale to remember the qualities and reproducibility, which are essential to the demands of industry as well as the medical world. The provision of manufacturing services includes the scale-up of processes from semilab scale to commercial and uniformity of batches, as well as compliance with regulatory requirements. The ways they facilitate prompt delivery and cost-effective production make them dominant in the markets when compared with other forms of services.

Which regions are leading the market, and why?

High growth is being observed in the North American nanoparticle contract manufacturing market owing to the rise in the pharmaceutical, biotechnology, and healthcare sectors. The region has superior research infrastructure and a large number of key players in the industry who have invested in nanotechnology-based drug delivery systems. The increasing focus on personalised medicine and precision treatments contributes to the growth of the market as well. There is additional regulatory support and increasing collaboration of contract manufacturers with research organisations that encourage innovation and production capabilities.

In their contributions to the market, the U.S. is leading with massive investments in nanotech research and development, whereas Canada and Mexico are making their contributions in emerging biotech ecosystems. There are obstacles like the high cost of production and process quality that still exist, but the existing technological development is making them overcome the impediments, and this is enabling North America to be an essential part of the international contract manufacturing industry in nanoparticles.

The Asia Pacific nanoparticle contract manufacturing market is growing rapidly, owing to the growth in the pharmaceutical, biotechnology, and cosmetics sectors. The most popular hubs include countries such as China, India, Japan, and South Korea, which provide affordable manufacturing resources and a resourceful scientific labour force. The market is growing due to the increasing government funding for nanotechnology research as well as the growing awareness of the need to have advanced drug delivery solutions.

Local manufacturers have also developed a trend of strategic alliances with international foreign companies to raise the capacity and overall adherence to international standards. Furthermore, the high patient population and the advancement in the healthcare infrastructure in the region are creating a demand for innovative nanomedicine in the region. Along with improved R&D and laudable regulatory policies, Asia Pacific is becoming a major competitor in the international nanoparticle contract manufacturing market.

What does the competitive landscape of the market look like?

The nanoparticle contract manufacturing market is highly competitive, and there are almost an equal number of contract manufacturing organisations specialised in nanotechnology to carry the flag of leading pharmaceutical companies. Investing in the most advanced nanoparticle synthesis and formulation technologies, the largest industry actors, such as AstraZeneca, Evonik Industries, CordenPharma, and Fortis Life Sciences, are sustaining their positions. Small, independent businesses such as Ascendia Pharmaceuticals and Nano Labs Corporation are catching up by offering highly customised and very flexible manufacturing solutions.

The most recent developments incorporate the expansion of facilities and strategic partnering to expand production capabilities and satisfy the emerging demand, mainly in lipid nanoparticles employed in mRNA vaccines. Such companies as Ardena Holding NV or BioVectra Inc. have been capable of broadening their service offerings and establishing themselves as an indispensable ally to pharmaceutical innovators by incorporating novel nanoparticle characterisation and scale-up methods. The fast rate of innovation through this competition ensures cost-effectiveness as well as reduced development periods of nanoparticle-based drugs.

Nanoparticle Contract Manufacturing Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the industry?

• In May 2025, a strategic market report identified over 30 nanoparticle CDMOs, including Evonik, Ardena, Ascendia, FUJIFILM, and Encapsula. These companies benefited from increased outsourcing in nanomedicine, LNP-mRNA therapies, and oncology formulations. The report also highlighted advances in PAT-driven quality control and AI-optimized process design. Overall, these factors contributed to their growth in the contract development and manufacturing sector.

Report Coverage:

By Nanoparticle Type

• Metallic Nanoparticles
• Polymeric Nanoparticles
• Lipid-Based Nanoparticles
• Ceramic Nanoparticles
• Carbon-Based Nanoparticles
• Quantum Dots
• Others

By Service Type

• Process Development
• Formulation Development
• Analytical & Characterization Services
• Manufacturing Services
• Packaging & Labeling Services
• Regulatory Consulting and Documentation

By Contract Type

• Custom Manufacturing
• Full-Service Manufacturing
• API & Intermediate Manufacturing

By End User

• Pharmaceutical & Biotechnology Companies
• Medical Device Manufacturers
• Academic & Research Institutions
• Cosmetic Companies
• Food & Beverage Companies
• Agrochemical Companies
• Environmental Agencies

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• AstraZeneca plc
• Evonik Industries AG
• CordenPharma International GmbH
• Ascendia Pharmaceuticals LLC
• Ardena Holding NV
• AVANSA Technology & Services
• BioVectra Inc.
• Fortis Life Sciences
• American Elements
• Nano Labs Corporation
• Nanoscale Corporation
• Nanoshel LLC
• NanoComposix, Inc.
• BBI Solutions
• Cytodiagnostics Inc.

Frequently Asked Questions (FAQs)